Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of UCB0942 in Healthy Japanese and Caucasian Subjects
NCT03168984Phase 1Completed
- Sponsor
- UCB
- Start
- May 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in epilepsy comparing UCB0942 with Placebo (2 arms). Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Plasma Concentration-Time Curve from Time Zero to Last Detectable Concentration. Started May 2017; status: completed.
02
Drugs
padsevonil
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03168984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03168984.